In this study, we investigated the anti-tumor efficacy of Nrf2 inhibitor, brusatol in combination with dual HER2/EGFR inhibitor, lapatinib and explored its potential mechanism of action as a new therapeutic regimen for HER2-positive cancers. This evidence concerns the gene EGFR and neoplasm.